Development of the treatment of cardiac failure using a nanosphere (NS) preparation encapsulated with a therapeutic agent for myocardial regeneration
| Project/Area Number |
26670616
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cardiovascular surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
SAWA Yoshiki 大阪大学, 医学(系)研究科(研究院), 教授 (00243220)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKUSHIMA Satsuki 大阪大学, 大学院医学系研究科, 助教 (80596867)
SOGAWA Nagako 大阪大学, 大学院医学系研究科, 特任研究員 (30432579)
IMANISHI Yukiko 大阪大学, 大学院医学系研究科, 特任研究員 (10707582)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 疾患特異的 / ナノスフェアー / 肺高血圧症 / 虚血性心筋症 / オキシム誘導体 / ｵｷｼﾑ誘導体 / DDS効果 / 心不全 |
|---|
| Outline of Final Research Achievements |
A nanosphere (NS) preparation has been created as a novel and disease-specific DDS preparation of oxime derivatives to develop a disease-specific treatment approach based on a less invasive and more versatile administration technique. A trial product of the NS preparation of oxime derivatives with the average particle size of 100 nm has been produced (in preparation for patent application). In a study, weekly intermittent intravenous administration of the NS preparation of oxime derivatives, repeated oral administration of oxime derivatives, and weekly intermittent intravenous administration of oxime derivatives were comparatively examined in rat models of monocrotaline-induced pulmonary hypertension and coronary total occlusion. As a result, DDS effects of the NS preparation of oxime derivatives have been confirmed. It is suggested that this NS preparation can be a disease-specific therapeutic agent for cardiac failure.
|
Report
(3 results)
Research Products
(4 results)
